Adagene Inc.
ADAG- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001818838
In the last 90 days, Adagene Inc. insiders filed 4 open-market purchases and 0 sales; 35 institutions reported holding it in 13F filings for Q2 2026, worth $81.0M in total; no superinvestor holds it.
13F holders, Q2 2021
Institutional positions in Adagene Inc. as of Jun 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 16
- −11 vs. Q1 2021
- Shares held
- 5.94M
- −497.3K (−7.7%) vs. Q1 2021
- Total value
- $80.5M
- −$35.0M (−30.3%) vs. Q1 2021
- New holders
- 1
- 5 more added
- Sold out
- 12
- 4 more reduced
Compare with Q1 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ADAG on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 35 | $81.0M |
| Q1 2026 | 25 | $9.70M |
| Q4 2025 | 17 | $6.03M |
| Q3 2025 | 17 | $11.3M |
| Q2 2025 | 15 | $11.8M |
| Q1 2025 | 14 | $11.6M |
| Q4 2024 | 15 | $20.3M |
| Q3 2024 | 13 | $25.3M |
| Q2 2024 | 14 | $33.7M |
| Q1 2024 | 17 | $34.3M |
| Q4 2023 | 11 | $15.5M |
| Q3 2023 | 10 | $6.16M |
| Q2 2023 | 10 | $6.02M |
| Q1 2023 | 11 | $6.02M |
| Q4 2022 | 9 | $5.58M |
| Q3 2022 | 11 | $7.60M |
| Q2 2022 | 15 | $15.4M |
| Q1 2022 | 15 | $29.7M |
| Q4 2021 | 16 | $67.3M |
| Q3 2021 | 19 | $126.6M |
| Q2 2021 | 16 | $80.5M |
| Q1 2021 | 27 | $115.5M |
Institutions, Q2 2021
Shares, value and share of portfolio for each institution holding Adagene Inc.; share changes are against Q1 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Morgan Stanley | 1,414,275 | $19.2M | 0.00% | +959,259+210.8% | Added |
| Artal Group S.A. | 1,000,000 | $13.6M | 0.31% | +200,000+25.0% | Added |
| Capital International Investors | 923,269 | $12.5M | 0.00% | 00.0% | Unchanged |
| Matthews International Capital Management LLC | 838,500 | $11.4M | 0.47% | 00.0% | Unchanged |
| Hudson Bay Capital Management LP | 331,543 | $4.50M | 0.06% | 00.0% | Unchanged |
| Capital International Inc | 304,876 | $4.13M | 0.04% | −77,838−20.3% | Reduced |
| OrbiMed Advisors LLC | 275,000 | $3.73M | 0.04% | 00.0% | Unchanged |
| General Atlantic LLC | 264,000 | $3.58M | 0.03% | 00.0% | Unchanged |
| Suvretta Capital Management, LLC | 204,000 | $2.77M | 0.04% | 00.0% | Unchanged |
| Strategic Vision Investment Ltd | 189,700 | $2.57M | 4.20% | −268,801−58.6% | Reduced |
| Trellus Management Company, LLC | 55,000 | $746.0K | 0.60% | +14,093+34.5% | Added |
| Tudor Investment Corp Et Al | 45,361 | $615.0K | 0.01% | −20.0% | Reduced |
| Alyeska Investment Group, L.P. | 40,000 | $542.0K | 0.01% | +29,488+280.5% | Added |
| Capital International Sarl | 28,392 | $385.0K | 0.03% | −7,334−20.5% | Reduced |
| Millennium Management LLC | 21,953 | $298.0K | 0.00% | +21,953 | New |
| UBS Group AG | 2,062 | $28.0K | 0.00% | +1,785+644.4% | Added |
| Credit Suisse AG | 0 | $0 | 0.00% | −605,638−100.0% | Sold out |
| Allianz Asset Management GmbH | 0 | $0 | 0.00% | −438,500−100.0% | Sold out |
| Caas Capital Management LP | 0 | $0 | 0.00% | −69,000−100.0% | Sold out |
| Citigroup Inc | 0 | $0 | 0.00% | −63,536−100.0% | Sold out |
| HSBC Holdings PLC | 0 | $0 | 0.00% | −48,702−100.0% | Sold out |
| Marshall Wace North America L.P. | 0 | $0 | 0.00% | −35,903−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −34,360−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −22,371−100.0% | Sold out |
| Two Sigma Investments, LP | 0 | $0 | 0.00% | −20,232−100.0% | Sold out |
| Pinz Capital Management, LP | 0 | $0 | 0.00% | −16,667−100.0% | Sold out |
| Norges Bank | 0 | $0 | 0.00% | −12,000−100.0% | Sold out |
| Legal & General Group Plc | 0 | $0 | 0.00% | −3,000−100.0% | Sold out |